Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tobramycin

FDA-approved product (solution/drops, ophthalmic), marketed as Aktob, Bethkis, Kitabis Pak and 8 more.

Registered studies
50+
Lab records
48
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Tobramycin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Allergic conjunctivitis
  • Bacterial disease
  • Cystic fibrosis
  • Eye infection
  • Infection
  • Inflammation
  • Respiratory tract infectious disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other aminoglycosides; Antibiotics
FDA pharmacologic class
Aminoglycoside Antibacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01GB01; WHO ATC S01AA12; FDA class Aminoglycoside Antibacterial

Repurposing investigation

Tobramycin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA4.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli4.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae51.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis66.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 3 of 10 lab records
  • E. coli: measured active in 6 of 15 lab records
  • K. pneumoniae: measured active in 17 of 23 lab records
Open Tobramycin in ChEMBL Registered studies below
Show the 48 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tobramycin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Does Administration of Antibiotics in Patients Undergoing Surgery for Colorectal Cancer Result in Less Complications and Better Prognosis?

    NCT01740947 · start 2013-01

    Registered record
    Registry ID
    NCT01740947
    Conditions
    Colorectal Cancer
    Interventions
    Selective decontamination of the digestive tract (SDD) (colistin sulfate, tobramycin, amphotericin B)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2013-01
    Completion
    2017-03
    Enrolment
    485

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    InterventionSelective decontamination of the digestive tract (SDD) (colistin sulfate, tobramycin, amphotericin B)
    PhasePhase 4
    Registry statusTerminated

  • Switching From Tobramycin Inhalation Treatment to Tobramycin Inhaler Treatment: The Effect on CF Patients' Adherence and Quality of Life

    NCT01749644 · start 2013-01

    Registered record
    Registry ID
    NCT01749644
    Conditions
    Alteration in Quality of Life of CF Patients, Following Change of Treatment From Antibiotic Inhalation to Antibiotic Inhaler
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2013-01
    Completion
    2015-01
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlteration in Quality of Life of CF Patients, Following Change of Treatment From Antibiotic Inhalation to Antibiotic Inhaler
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • Efficacy of Over the Counter (OTC) Povidone-Ioldine 5% for Treatment of Acute or Chronic Blepharitis

    NCT01560962 · start 2012-01

    Registered record
    Registry ID
    NCT01560962
    Conditions
    Blepharitis
    Interventions
    povidone iodine; No Intervention; Azithromycin; tobramycin-dexmethasone; warm soaked eyelid wash
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2012-01
    Completion
    2012-12
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBlepharitis
    Interventionpovidone iodine; No Intervention; Azithromycin; tobramycin-dexmethasone +1 more
    PhaseNot applicable
    Registry statusTerminated

  • Circadian Rhythm In Tobramycin Elimination In Cystic Fibrosis

    NCT01207245 · start 2011-05

    Registered record
    Registry ID
    NCT01207245
    Conditions
    Cystic Fibrosis
    Interventions
    Tobramycin time of administration
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-05
    Completion
    2012-06
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis
    InterventionTobramycin time of administration
    PhasePhase 4
    Registry statusCompleted

  • Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus® /Pulmoaid® in Patients With Cystic Fibrosis

    NCT01337219 · start 2011-04

    Registered record
    Registry ID
    NCT01337219
    Conditions
    Cystic Fibrosis
    Interventions
    Tobramycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2011-04
    Completion
    Not recorded
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis
    InterventionTobramycin
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • A Study to Evaluate the Clinical Efficacy and Safety of Tobradex® ST Compared to Azasite® in the Treatment of Subjects With Moderate to Severe Chronic Blepharitis

    NCT01102244 · start 2010-04

    Registered record
    Registry ID
    NCT01102244
    Conditions
    Blepharitis
    Interventions
    Tobradex ST; Azasite
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-04
    Completion
    Not recorded
    Enrolment
    122

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBlepharitis
    InterventionTobradex ST; Azasite
    PhasePhase 3
    Registry statusCompleted

  • Duration of Antibiotics in Infective Exacerbations of Cystic Fibrosis

    NCT01044719 · start 2010-01

    Registered record
    Registry ID
    NCT01044719
    Conditions
    Cystic Fibrosis
    Interventions
    Ceftazidime; Tobramycin; Meropenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2010-01
    Completion
    2011-04
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis
    InterventionCeftazidime; Tobramycin; Meropenem
    PhasePhase 4
    Registry statusUnknown

  • A Study of Tobramycin Inhalation Powder From a Modified Manufacturing Process Versus Placebo

    NCT00918957 · start 2009-06

    Registered record
    Registry ID
    NCT00918957
    Conditions
    Cystic Fibrosis
    Interventions
    Tobramycin Inhalation Powder; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-06
    Completion
    2011-05
    Enrolment
    62

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis
    InterventionTobramycin Inhalation Powder; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Tobramycin-Dexamethasone Versus Tobramycin-Dexamethasone Plus Ketorolac After Phacoemulsification Surgery

    NCT00992355 · start 2009-01

    Registered record
    Registry ID
    NCT00992355
    Conditions
    Cataract
    Interventions
    Tobramycin 0.3% - Dexamethasone 0.1%; Tobramycin 0.3% - Dexamethasone 0.1% plus Ketorolac tromethamine 0.5%
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2009-01
    Completion
    2009-04
    Enrolment
    97

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCataract
    InterventionTobramycin 0.3% - Dexamethasone 0.1%; Tobramycin 0.3% - Dexamethasone 0.1% plus Ketorolac tromethamine 0.5%
    PhaseNot applicable
    Registry statusCompleted

  • Clinical Efficacy and Safety of T1225 Versus Tobramycin 0.3 % Eye Drops in the Treatment of Purulent Bacterial Conjunctivitis of Children.

    NCT01155999 · start 2008-12

    Registered record
    Registry ID
    NCT01155999
    Conditions
    Purulent Bacterial Conjunctivitis
    Interventions
    T1225; Tobramycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-12
    Completion
    2011-02
    Enrolment
    286

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPurulent Bacterial Conjunctivitis
    InterventionT1225; Tobramycin
    PhasePhase 3
    Registry statusCompleted

  • Study Evaluating Fosfomycin/Tobramycin for Inhalation in Cystic Fibrosis Patients With Pseudomonas Aeruginosa Lung Infection

    NCT00794586 · start 2008-11

    Registered record
    Registry ID
    NCT00794586
    Conditions
    Cystic Fibrosis
    Interventions
    FTI, AZLI; Placebo, AZLI
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-11
    Completion
    2010-03
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis
    InterventionFTI, AZLI; Placebo, AZLI
    PhasePhase 2
    Registry statusCompleted

  • Tobramycin Tear Concentrations

    NCT00695435 · start 2008-06

    Registered record
    Registry ID
    NCT00695435
    Conditions
    Dry Eye
    Interventions
    TOBRADEX Ophthalmic Suspension; Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension; TOBREX Ophthalmic Solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-06
    Completion
    Not recorded
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDry Eye
    InterventionTOBRADEX Ophthalmic Suspension; Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension; TOBREX Ophthalmic Solution
    PhasePhase 1
    Registry statusCompleted

  • Study of T-PRED(TM) Compared to Pred Forte(R)

    NCT00699803 · start 2008-05

    Registered record
    Registry ID
    NCT00699803
    Conditions
    Cataract
    Interventions
    T-PRED; Pred Forte
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-05
    Completion
    2008-08
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCataract
    InterventionT-PRED; Pred Forte
    PhasePhase 2
    Registry statusCompleted

  • Tobradex BID Compared to TOBRADEX and TOBREX/Vehicle

    NCT00404937 · start 2006-12

    Registered record
    Registry ID
    NCT00404937
    Conditions
    Post-surgical Inflammation
    Interventions
    Tobradex (Antibiotic steroid combination)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2006-12
    Completion
    2006-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPost-surgical Inflammation
    InterventionTobradex (Antibiotic steroid combination)
    PhasePhase 3
    Registry statusWithdrawn

  • Evaluating SPRC-AB01 in Post-Surgical Subjects With Chronic Sinusitis

    NCT00447837 · start 2006-10

    Registered record
    Registry ID
    NCT00447837
    Conditions
    Chronic Sinusitis
    Interventions
    SPRC-AB01
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-10
    Completion
    2008-01
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Sinusitis
    InterventionSPRC-AB01
    PhasePhase 2
    Registry statusCompleted